Price movement over the last 24 hours
Abeona Therapeutics Inc vs Valero Energy Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Valero Energy Corporation trades at $277.63 (market cap $79.05B). The key difference: Valero Energy Corporation is far larger — about 211.7× Abeona Therapeutics Inc's market cap, and Valero Energy Corporation pays a 1.8% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | VLO | |
|---|---|---|
Market Cap | $373.32M | $79.05B |
Sector | Health | Energy |
52-Week High | $7.23 | $270.32 |
52-Week Low | $4.17 | $131.77 |
Enterprise Value | $228.22M | $84.81B |
Dividend Yield | — | 1.8% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Valero Energy (VLO) trades at $266.22, down 0.58% on the day, with strong technical momentum showing bullish moving averages and key resistance at $270. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 expected at $10.08 EPS. Fundamentals show solid profitability with 17.72% ROE and attractive valuation metrics including P/E of 19.75 and P/S of 0.66. Recent news highlights VLO's refining strength and renewable fuels growth potential.
VLO presents a compelling investment case with strong analyst support (58% buy ratings) and a consensus price target of $258.25. The company's Gulf Coast refining advantage and clean-fuel initiatives support long-term growth, though investors face risks from energy market volatility and declining revenue trends from $176.4B in 2022 to $122.7B in 2025. The current price near resistance levels suggests potential for breakout or consolidation.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →